Shanghai Chia Tai Tianqing Pharmaceutical Technology Development

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development serves as the primary research and development engine for the Chia Tai Tianqing Pharmaceutical Group. Located in Shanghai's Zhangjiang Hi-Tech Park, the company focuses on the discovery and clinical advancement of innovative therapies in oncology, liver disease, respiratory health, and infectious diseases. It has been instrumental in developing the group's flagship innovative products, such as the multi-target kinase inhibitor anlotinib. The center utilizes advanced platforms for both small molecule and biologics discovery to maintain a competitive pipeline of first-in-class and best-in-class candidates. As a key subsidiary within the Sino Biopharmaceutical ecosystem, it plays a vital role in the group's transition from a generic manufacturer to a global innovation-led biopharmaceutical leader.